Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGJYZ8)

• Drug Name: EDP-305 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-alcoholic steatohepatitis	DB92.1	Phase 2	[1]
Primary biliary cholangitis	DB96.1	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 121428882
  TTD Drug ID: DMGJYZ8

Molecule-Related Drug Atlas

Drug(s) Targeting Farnesoid X-activated receptor (FXR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[4]
Guggulsterone	DMP7LK1	Osteoarthritis	FA00-FA05	Approved	[5]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[6]
GS-9674	DM936V7	Primary sclerosing cholangitis	DB96.2	Phase 3	[7]
Apomine	DM6B9HP	Osteopetrosis	LD24.10	Phase 2	[8]
LJN452	DM3XRUH	Primary biliary cholangitis	DB96.1	Phase 2	[9]
EYP001	DM5PBLM	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[10]
LMB763	DMQOXNL	Diabetic nephropathy	GB61.Z	Phase 2	[11]
MET409	DM89QXT	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[12]
Turofexorate isopropyl	DM36ONA	Hyperlipidaemia	5C80	Phase 1	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Farnesoid X-activated receptor (FXR)	TTS4UGC	NR1H4_HUMAN	Agonist	[3]

References

• [1] ClinicalTrials.gov (NCT04378010) A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT03394924) A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis. U.S. National Institutes of Health.
• [3] A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669.
• [4] Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
• [5] Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8.
• [6] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [7] The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801.
• [8] The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
• [9] FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
• [10] Clinical pipeline report, company report or official report of ENYO Pharma.
• [11] Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880.
• [12] Clinical pipeline report, company report or official report of Metacrine.
• [13] A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G543-52.